Aquaretics

Bibliography

• Urban IJA, Burbach JPH, De Wied D (Eds.), Elsevier Science By, Amsterdam, Netherlands (1998) 119:143–158.
   Google Scholar
• ••Review of the molecular pharmacology of vasopressin/oxytocin receptor subtypes.
   Google Scholar
• MICHELL RH, KIRK JC: Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. (1979) 7:861–865.
   PubMedGoogle Scholar
• Zingg H, Bourque CW, Bichet D (Eds.), Plenum Press, New York, USA (1998) 449:251–276.
   Google Scholar
• Saito T, Kurokawa K, Yoshida S (Eds.), Elsevier Science, Amsterdam, Netherlands (1995) :605–613.
   Google Scholar
• ••Review of mutations identified in patients with nephrogenic diabetes insipidus.
   Google Scholar
• HAYASHI M, SASAKI S, TSUGANEZAWA H, et al.: Expression and distribution of aquaporin of collecting duct are regulated by vasopressin V2 receptor in rat kidney. J. Clin. Invest. (1994) 94:1778–1783.
   PubMed Web of Science ®Google Scholar
• KNEPPER MA: Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. (1997) 272:F3–F12.
   PubMed Web of Science ®Google Scholar
• THIBONNIER M: Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Exp. Opin. Invest. Drugs (1998) 7:729–740.
   PubMedGoogle Scholar
• FREIDINGER RM, PETTIBONE DJ: Small molecule ligands for oxytocin and vasopressin receptors. Med. Res. Rev. (1997) 17:1–16.
   PubMed Web of Science ®Google Scholar
• •Review of the development of non-peptide AVP/OT analogues.
   Google Scholar
• ALBRIGHT JD, CHAN PS: Recent advances in the discovery and development of vasopressin antagonists: peptide and non-peptide Via and V2 receptor antagonists. Curr. Pharm. Des. (1997) 3:615–632.
   Web of Science ®Google Scholar
• ANDERSON RJ, CHUNG H, KLUGE R, SCHRIER RW: Hyponatraemia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann. Intern. Med. (1985) 102:164–168.
   PubMed Web of Science ®Google Scholar
• Brenner BM (Ed.), WB Saunders Co., Philadelphia, USA (1996) 5:878–928.
   Google Scholar
• ••Fundamental review of vasopressin physiology.
   Google Scholar
• AYUS JC, ARIEFF Al: Pathogenesis and prevention of hyponatremic encephalopathy. Endocrinol. Metab. Clin. North Am. (1993) 22:425–446.
   PubMed Web of Science ®Google Scholar
• ••Pathophysiology of hyponatraemic encephalopathy.
   Google Scholar
• LAURIAT SM, BERL T: The hyponatremic patient: practical focus on therapy. J. Am. Soc. Nephrol. (1997) 8:1599–1607.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the approach of a patient with hyponatraemia.
   Google Scholar
• MARPLES D, CHRISTENSEN S, CHRISTENSEN E, OTTOSEN P, NIELSEN S: Lithium-induced downregulation of aquaporin-2 channel expression in rat kidney medulla. J. Clin. Invest. (1995) 95:1838–1845.
   PubMed Web of Science ®Google Scholar
• SOUPART A, DECAUX G: Therapeutic recommendations for management of severe hyponatremia. Clin. Nephrol. (1996) 46:149–169.
   PubMed Web of Science ®Google Scholar
• •Overview of the medical treatment of SIADH.
   Google Scholar
• WELLS T, FORSLING ML: Kappa-opioid modulation of vasopressin secretion in conscious rats. J. Endocrinol. (1991) 129:411–416.
   PubMed Web of Science ®Google Scholar
• BELLISSANT E, DENOLLE T, SINNASSAMY P, et al.: Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers. J. Pharmacol. Exp. Ther. (1996) 278:232–242.
   PubMed Web of Science ®Google Scholar
• LASLO FA, LASLO F, DE WIED D: Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. (1991) 43:73–108.
   PubMed Web of Science ®Google Scholar
• KINTER LB, CALTABIANO S, HUFFMAN WF: Anomalous antidiuretic activity of antidiuretic hormone antagonists. Biochem. Pharmacol. (1993) 45:1731–1737.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y, OGAWA H, CHIHARA T, et al.: OPC-21268, an orally effective nonpeptide vasopressin VI receptor antagonist. Science (1991) 252:572–574.
   PubMed Web of Science ®Google Scholar
• OKADA K, ISHIKAWA S, SAITO T: Effect of a new Vi antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1991) 178(2):707–712.
   PubMed Web of Science ®Google Scholar
• LI X, KRIBBEN A, WIEDER ED, NEMENOFF RA, SCHRIER RW: Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268. Hypertension (1994) 23:217–222.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y, OGAWA H, YAMASHITA H: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2-receptor antagonist. Br. J. Pharmacol. (1992) 105:787–792.
   PubMed Web of Science ®Google Scholar
• BURRELL LM, PHILLIPS PA, STEPHENSON JM, RISVANIS J, ROLLS KA, JOHNSTON CI: Blood pressure lowering effect of an orally active vasopressin Vi receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension (1994) 23:737–743.
   PubMed Web of Science ®Google Scholar
• KITIYAKARA C, WILCOX CS: Vasopressin V2-receptor antagonists: panaceas for hyponatremia Curr. Opin. Nephr. Hyper. (1997) 6:461–467.
   PubMed Web of Science ®Google Scholar
• •Recent review of the therapeutic use of AVP V, receptor antagonists.
   Google Scholar
• OHNISHI A, ORITA Y, OKAHARA R, et al.: Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men./ Clin. Invest. (1993) 92:2653–2659.
   Google Scholar
• SAITO T, ISHIKAWAS, ABE K, et al.: Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J. Clin. Endocrinol. Metab. (1997) 82:1054–1057.
   PubMed Web of Science ®Google Scholar
• INOUE T, OHNISHI A, MATSUO A, et al.: Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin. Pharmacol. Ther. (1998) 63:561–570.
   PubMed Web of Science ®Google Scholar
• ALBRIGHT JD, REICH MF, DELOS SANTOS EG, et al.: 5-fluoro-2-methyl-N-J4-(5H-pyrrolo [2,1-c] -[1,4] benz odiazep in - 10 (11H) -ylcarbonyl) -3 -chlorophenyl] be nzamide (VPA985): an orally active arginine vasopressin antagonist with selectivity for V2 recep-tors. J. Med. Chem. (1998) 41:2442–2444.
   PubMed Web of Science ®Google Scholar
• LAI F, SHEPERD C, BAILEY T, CHAN PS, CERVONI P: Effects of the vasopressin V2 antagonist VPA-985 in rat caudal arteries and on arterial pressure in normotensive, SHR, and DOCA-salt hypertensive rats. 1997 World Congress of Neurohypophysial Hormones. Montréal, Canada (1997).
   Google Scholar
• ABRAHAM WT, OREN RM, SCHRIER RW: Effects of an oral nonpepide, selective V2 receptor antagonist in human heart failure. 1997 World Congress of Neurohyphysial Hormones. Montréal, Canada (1997).
   Google Scholar
• SERRADEIL-LE GAL C, LACOUR C, VALETTE G, et al.: Characterization of SR-121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. (1996) 98:2729–2738.
   PubMed Web of Science ®Google Scholar
• TOMITA M, NAGASHIMA A, SOGABE K, SHIMOMURA K: Pharmacological profiles of FR161282, a new nonpeptide vasopressin V2 receptor antagonist. Jpn. J. Pharmacol. (1997) 73 (Suppl. 1) :136P.
   Google Scholar
• ZENKOH J, ARAMORI I, MORIKAWAN et al.: Subtype-selectivity of a vasopressin receptor antagonist, FR161282, for cloned human vasopressin receptors. Jpn. J. Pharmacol. (1997) 73\(Suppl. 1):136P.
   Google Scholar
• SLADEK CD, BLAIR MI, MANGIAPANE M: Evidence against a pressor role for vasopressin in spontaneous hypertension. Hypertension (1987) 9:332–338.
   PubMed Web of Science ®Google Scholar
• SLADEK C, BLAIR ML, STERLING C, MANGIAPANE ML: Attenuation of spontaneous hypertension in rats by a vasopressin antagonist. Hypertension (1988) 12:506–512.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the role of peptide antagonists in the blood pressure control of SHRanimals.
   Google Scholar
• HOFBAUER KG, MAH SC, BAUM HP, HANNI H, WOOD JM, KRAETZ J: Endocrine control of salt and water excretion: the role of vasopressin in DOCA-salt hypertension. J. Cardiovasc. Pharmacol. (1984) 6 (Suppl.) :184–191.
   Web of Science ®Google Scholar
• TAHARA A, TOMURA Y, WADA KI, et al.: Pharmacological profile of YM087, a novel potent nonpeptide vasopressin Via and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. (1997) 282:301–308.
   Google Scholar
• FRICKER AF, BURNIER M, BRUNNER HR: Evaluation of the non-peptide. orally active, Vi/V2 receptor antagonist YM087 in normal subjects. 1997 World Congress of Neurohypophysial Hormones. Montréal, Canada (1997).
   Google Scholar
• HARTUPEE DA, COUPET J, VENKATESAN AM, CERVONI P, SPINELLI W: Effects of CL-385004, a nonpeptidic vasopressin Via/V2 receptor antagonist, in a rat model of heat failure. Circulation (1997) 96:1611–1612.
   Web of Science ®Google Scholar
• ARROYO V, CLARIA J, SALO J, JIMENEZ W: Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin. Liver Dis. (1994) 14:44–58.
   PubMed Web of Science ®Google Scholar
• GINES P, ABRAHAM WT, SCHRIER RW: Vasopressin in pathophysiological states. Semin. Nephrol. (1994) 14:384–397.
   PubMed Web of Science ®Google Scholar
• ••Description of the role of vasopressin in hyponatraemia of liver cirrhosis and heart failure.
   Google Scholar
• OKADA H, SUZUKI H, KANNO Y, SARUTA T: Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron (1996) 72:667–672.
   PubMedGoogle Scholar
• GOODFRIEND TL, ELLIOTT ME, CATT KJ: Angiotensin receptors and their antagonists. New Engl. J. Med. (1996) 334:1649–1654.
   PubMed Web of Science ®Google Scholar
• Bowman WC, Fitzgerald JD, Taylor JB (Eds.), Ashley Publications Ltd., London, UK (1998) 3:81–93.
   Google Scholar
• BERNAT A, HOFFMANN P, DUMAS A, SERRADEIL-LE GAL C, RAUFASTE D, HERBERT JM: V2 receptor antagonism of dDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Ther. (1997) 282:597–602.
   PubMed Web of Science ®Google Scholar